摘要
目的研究依折麦布联合辛伐他汀对急性冠脉综合征(ACS)患者血脂达标率的影响。方法入选初次就诊诊断的ACS患者80例,随机分为2组,各40例。辛伐他汀组给予辛伐他汀(40mg/d)治疗,联合组给予辛托伐他汀(40mg/d)和依折麦布(10mg/d)联合治疗,6周后比较两组患者血脂达标率及不良反应。结果与治疗前相比,两组的总胆固醇、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油水平均有明显降低;与治疗前比较,联合组的HDL-C水平上升,差异无统计学;LDL-C的调脂幅度和LDL-C的达标率均高于辛伐他汀组。联合组不良反应发生率与辛伐他汀组比较,差异无统计学意义(P>0.05)。结论依折麦布联合辛伐他汀可以有效治疗ACS患者的血脂,并提高其达标率,优于单用辛伐他汀。依折麦布联合辛伐他汀联合可应用于ACS的初始降脂治疗。
Objective To research the systematic rate of ezetimibe combined with simvastatin on blood lipids in pa- tients with acute coronary syndrome （ACS）. Methods All the ACS patients were diagnosis first, 80 cases were randomly di- vided into two groups, one group given simvastatin （ 40mg/d ）, another group given simvastatin （40mg/d） and ezetimibe （10mg/d） combination, blood lipids compliance rate and adverse reactions incidcncewere compared after 6 weeks. Results Compared with before the treatment, the two groups in total cholesterol, LDL, triglyceride levels were significantly reduced; compared with before the treatment of HDL - C level of the joint group increased, but no significant difference; LDL - compli- ance rates of the lipid was higher than simvastatin group. The incidence of adverse reactions of the combined group was no signifi- cant differencecompared with the simvastatin group. Conclusion ezetimibe combined with simvastatin can increase the compli- ance rate of serum lipids in patients with ACS, better than simvastatin, and security; ezetimibecombined with simvastatin can be applied to the initial lipid -lowering therapy in ACS.
出处
《实用心脑肺血管病杂志》
2012年第10期1607-1609,共3页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
